[Strategies for liver injury caused by hepatocellular carcinoma targeted therapy]

Zhonghua Gan Zang Bing Za Zhi. 2023 Nov 20;31(11):1129-1132. doi: 10.3760/cma.j.cn501113-20230905-00090.
[Article in Chinese]

Abstract

Primary hepatocellular carcinoma has a high degree of malignancy, insidious onset, and rapid progression that seriously threatens human life and health. With the continuous deepening of the study of the molecular characteristics of tumors, molecular targeted drugs have become an important treatment method for patients with advanced liver cancer. Liver injury is one of the common adverse reactions of targeted drugs, which needs to be paid attention to. This paper mainly briefly expounds on the occurrence condition, mechanism, risk factors, diagnosis, and treatment of liver injury caused by hepatocellular carcinoma targeted therapy in order to provide a reference for the safe clinical application of targeted drugs.

原发性肝细胞癌恶性程度高,起病隐匿且发展迅速,严重威胁人类的生命和健康。随着对肿瘤分子学特征研究的不断深入,分子靶向药物已成为晚期肝癌患者的重要治疗手段。肝损伤是靶向药物常见的不良反应之一,需引起重视。现主要从肝癌靶向药物导致肝损伤的发生情况、机制、危险因素、诊断和治疗等方面做简要阐述,以期为肝癌患者临床安全应用靶向药物提供参考。.

Keywords: Drug-induced liver injury; Hepatocellular carcinoma; Targeted therapy.

Publication types

  • English Abstract

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Humans
  • Immunotherapy
  • Liver Neoplasms* / pathology
  • Molecular Targeted Therapy / adverse effects
  • Molecular Targeted Therapy / methods